Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05241275 · ClinicalTrials.gov registry record · Phase 2

Xenon MRI and Progressive ILD

A Phase 2 study of Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis, sponsored by Duke University.

Active
Registry status
Phase 2
Development phase
60
Enrollment target
1
Study location

NCT05241275 is a Phase 2 study of Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis that is active but no longer recruiting, run by Duke University. The registered enrollment target is 60 participants, below the 750-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05241275, a Phase 2 study of Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis, is active but no longer recruiting, sponsored by Duke University.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

The XENON ILD study is a single arm, un-blinded study at Duke University enrolling patients with non-idiopathic pulmonary fibrosis (IPF) progressive fibrosis (PF) interstitial lung disease (ILD). Patients who meet criteria for ILD-progression (defined below in inclusion/exclusion criteria) will be consented prior to the initiation of anti-fibrotic therapy. Subjects will undergo an approximately hour long comprehensive MRI protocol, including administration of multiple doses of hyperpolarized 129Xe. The subjects will have this initial study prior to initiation of anti-fibrotic therapies and repeat MRI studies at 3, 6 and 12 months following the initiation of therapy. If subjects do not decide to initiate anti-fibrotic therapy per discussion with their physician, then the 3, 6 and 12 months repeat studies will initiate based on time after enrollment.

Conditions Studied

Idiopathic Pulmonary Fibrosis Progressive Pulmonary Fibrosis

Interventions

  • DRUG Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment

Study Locations (1)

North Carolina

  • Duke University - Durham

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2022-07-19
Est. Completion 2026-08-31
Phase Phase 2

Sponsor

Duke University

1,725 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05241275

The ClinicalTrials.gov registry entry for NCT05241275 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 750-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (92% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment is the first listed.

NCT05241275 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT05241275 about?

NCT05241275 is a clinical study titled "Xenon MRI and Progressive ILD". The XENON ILD study is a single arm, un-blinded study at Duke University enrolling patients with non-idiopathic pulmonary fibrosis (IPF) progressive fibrosis (PF) interstitial lung disease (ILD). Patients who meet criteria for ILD-progression (defined below in inclusion/exclusion criteria) will be c...

What is the current status of trial NCT05241275?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2022-07-19. Estimated completion is 2026-08-31.

What conditions does trial NCT05241275 study?

This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis.

What interventions are being tested in trial NCT05241275?

The interventions under investigation include: Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment (DRUG).

Who is sponsoring clinical trial NCT05241275?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05241275 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Idiopathic Pulmonary Fibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Idiopathic Pulmonary Fibrosis

All registered trials for this condition

Progressive Pulmonary Fibrosis

All registered trials for this condition

North Carolina

All trials with a study site in North Carolina

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.